Matinas BioPharma Holdings, Inc. (MTNB) stock
MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Earnings
Matinas BioPharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2024
–
EPS, Q2 FY2024
-$0.02
-$0.03 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Matinas BioPharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024during market hours | – | – | -$0.02 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024during market hours | – | – | -$0.03 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 27, 2024during market hours | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023during market hours | – | – | -$0.03 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023during market hours | – | – | -$0.03 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023during market hours | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 15, 2023during market hours | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022during market hours | $1.10M | – | -$0.03 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022before the open | $1.10M | – | -$0.03 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 8, 2022before the open | – | – | -$0.03 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021before the open | – | – | -$0.03 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 29, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 6, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020during market hours | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 11, 2020during market hours | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 9, 2020during market hours | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 13, 2019before the open | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 14, 2019before the open | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Aug 8, 2017before the open | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | Apr 3, 2017before the open | – | – | – | Filing |
| Q4 FY2014ended Dec 31, 2014 | Mar 19, 2015before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Matinas BioPharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Matinas BioPharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Matinas BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- News
- News
- News
- News
- Update
- Results
- Results
- Results
- Update
- Update
- Results
- Update
- Update
See a number that looks wrong?